Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease Data Presented During ASN Kidney Week 2023 Demonstrate Significant Reversal of Albuminuria in Chronic Disease Model First-in-Human Trial of MZE829 Development…
Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria Findings to be Presented During Poster Session at Kidney Week 2023 SOUTH SAN FRANCISCO, CA., October 13, 2023–Maze Therapeutics, a company…
Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease Findings Published in JASN in Partnership with the Million Veteran Program and Vanderbilt University Medical Center SOUTH…
Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference SOUTH SAN FRANCISCO, CA., September 21, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will participate in a fireside chat…
Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference SOUTH SAN FRANCISCO, CA., June 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023…
Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference SOUTH SAN FRANCISCO, CA., June 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023…
Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease MZE001 was Well-tolerated and Reduced Glycogen Accumulation in Blood Cells and Muscle in Healthy Volunteers Maze to Receive…
Data Further Supports Proof of Mechanism for MZE001, an Oral Substrate Reduction Therapy, with approximately 60% Reduction in Muscle Glycogen in Healthy Volunteers Non-invasive Biomarker Developed by Maze to Measure Glycogen Levels Suggests Approximately 1:1 Correlation Between PBMC Blood Test…
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease MZE001 Was Well Tolerated and Reduced Glycogen Accumulation in Blood Cells in Healthy Volunteers Phase 1 Results Support Advancement into…
Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease MZE001 was Well-Tolerated and Reduced Glycogen Accumulation in Blood Cells in Healthy Volunteers, Supporting Advancement into Phase 2 Clinical Trial SOUTH…